Synthetic peptide within Human xCT aa 1-50 (N terminal). The exact sequence is proprietary.
Sequence:
MVRKPVVSTISKGGYLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGV
Our Abpromise guarantee covers the use of ab37185 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | Use a concentration of 0.5 - 2 µg/ml. Predicted molecular weight: 55 kDa. xCT forms heterodimer with 4F2Hc protein hence reducing conditions should be used in WB. It exists as multi-pass membrane protein therefore we recommend heating the lysates for 15-20 minutes at 60-70C. |
|
Flow Cyt | Use a concentration of 2 - 3 µg/ml. ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody. |
|
IHC-P | Use a concentration of 5 µg/ml. | |
ICC/IF | 1/100 - 1/1000. | |
IHC-FoFr | Use at an assay dependent concentration. PubMed: 21639880 |
Imunocytochemistry/ Immunofluorescence analysis of HepG2 cells labeling xCT with ab37185 followed by Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red) respectively.
Immunohistochemical analysis of small intestine labeling xCT with ab37185. Staining is observed in the absorptive epithelia of small intestinal villi.
PFA perfusion fixed frozen sections of spinal cord of control (left) and MS patients (right) stained for xCT using ab37185 at 5 µg/ml.
This experiment was performed under reducing conditions using the 12-230 kDa separation system. * Non-specific interaction with the 230 kDa.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"